Compare NTST & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | AMLX |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2020 | 2021 |
| Metric | NTST | AMLX |
|---|---|---|
| Price | $20.57 | $14.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 9 |
| Target Price | ★ $22.02 | $21.56 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 04-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | ★ 150.00 | 65.46 |
| EPS | ★ 0.06 | N/A |
| Revenue | $195,006,000.00 | ★ $380,786,000.00 |
| Revenue This Year | $19.03 | N/A |
| Revenue Next Year | $16.25 | N/A |
| P/E Ratio | $345.08 | ★ N/A |
| Revenue Growth | 19.79 | ★ 1612.94 |
| 52 Week Low | $15.37 | $4.64 |
| 52 Week High | $21.30 | $18.61 |
| Indicator | NTST | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 39.18 |
| Support Level | $19.98 | $13.57 |
| Resistance Level | $21.24 | $15.37 |
| Average True Range (ATR) | 0.33 | 0.85 |
| MACD | -0.02 | -0.32 |
| Stochastic Oscillator | 66.67 | 11.17 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.